The approach to the development of new psychiatric drugs is frequently criticized for being inefficient, slow, and plagued by dated methods and archaic outcome measures.1,2 For the US Food and Drug Administration (FDA), the rate of success for new drug candidates has decreased over the past decades, owing in part to increasing response to placebo and decreasing response to treatment.3 It may seem excessive to say, “the clinical trials system is broken,” but this statement is the verbatim title of at least 1 publication.4 Even the most ardent defenders of the status quo may admit that some things need to change.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Opler MGA, Shen Y. Modified Positive and Negative Syndrome Scale—A Journey of a Thousand Miles Starts With the First Step. JAMA Psychiatry. Published online July 01, 2020. doi:10.1001/jamapsychiatry.2020.1288
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: